Professor Iain Keenan
Emily Green
Dr Emma Haagensen
Dr Rebecca Hancock
Kayleigh Scotcher
et al. | Pandemic-Era Digital Education: Insights from an Undergraduate Medical Programme | 2022 |
|
Dr Timothy Barrow
Dr Sirintra Nakjang
Kateryna Bilotkach
Dr Laura Woodhouse
Gesa Junge
et al. | Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia | 2021 |
|
Dr Carmela Ciardullo
Erhan Aptullahoglu
Dr Laura Woodhouse
Dr Wei-Yu Lin
Dr Jonathan Wallis
et al. | Non-genotoxic MDM2 inhibition selectively induces pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells | 2019 |
|
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Dr Laura Woodhouse
Dr Aiste McCormick
Professor Richard Edmondson
et al. | Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity | 2016 |
|
Dr Laura Woodhouse
Professor David Kennedy
Emeritus Professor Brian Lunn
| Candidate use of a feedback site and how that relates to examination performance | 2016 |
|
Dr Laura Woodhouse
Emeritus Professor Brian Lunn
Professor David Kennedy
| Comparison of Cohen and Angoff methods of standard setting: is Angoff worth it? | 2016 |
|
Dr Laura Woodhouse
Professor Richard Edmondson
| Ovarian Cancer | 2016 |
|
Dr Timothy Barrow
Dr Laura Woodhouse
Gesa Junge
Dr Susan Tudhope
Dr Jonathan Wallis
et al. | The Role of HOXA4 in Chronic Lymphocytic Leukaemia Progression and Response to Therapy | 2016 |
|
Dr Laura Woodhouse
Clark Crawford
Dr Scott Marshall
Dr Nicholas Bown
Dr Elaine Willmore
et al. | Assessment and targeting of the MDM2-p53 network in CLL | 2015 |
|
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Patterson
et al. | PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia | 2015 |
|
